AZN: 阿斯利康

AZN新闻

• 12:11 阿斯利康在美国推出 ZEGFROVY，拓展 EGFR 外显子 20 插入突变肺癌的靶向治疗选择
• 12:11 AstraZeneca Launches ZEGFROVY In The U.S., Expanding Targeted Treatment Options For EGFR Exon 20 Insertion-Mutated Lung Cancer
• 06:49 Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks
• 14:00 Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
• 12:30 Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
• 11:45 Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings (NYSE:BMY)
• 05:24 Omeros: The Trade After European Rejection (NASDAQ:OMER)
• 16:51 AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
• 16:51 阿斯利康/安进药物在嗜酸性食管炎研究中显示出显著缓解
• 13:25 GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
• 13:06 Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
• 13:06 AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
• 09:29 Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research
• 05:13 甲骨文宣布与阿斯利康达成非约束性协议，探索将人工智能和真实世界数据用于临床试验患者识别、证据生成和护理洞察
• 05:13 Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights
• 12:38 Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
• 12:38 诺瓦瓦克斯第二大股东抛售3260万美元股票，结束激进施压
• 12:00 The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
• 11:10 AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026
• 12:45 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
• 21:15 Astrazeneca (AZN) Rises Higher Than Market: Key Facts
• 17:17 Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
• 14:52 阿斯利康转向人工智能，在十亿美元交易中攻克棘手的心脏和肝脏疾病
• 14:52 AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal